Medicenna Therapeutics Corp.

OTCPK:MDNA.F Stock Report

Market Cap: US$27.9m

Medicenna Therapeutics Future Growth

Future criteria checks 2/6

Medicenna Therapeutics is forecast to grow earnings and revenue by 1.4% and 62.8% per annum respectively. EPS is expected to grow by 0.2% per annum. Return on equity is forecast to be 14% in 3 years.

Key information

1.4%

Earnings growth rate

0.23%

EPS growth rate

Biotechs earnings growth25.2%
Revenue growth rate62.8%
Future return on equity13.96%
Analyst coverage

Low

Last updated21 Apr 2026

Recent future growth updates

Recent updates

Seeking Alpha • Sep 30

Medicenna extends period to exercise certain warrants

Medicenna Therapeutics (NASDAQ:MDNA) received conditional approval from the TSX to extend the expiry date of the common share purchase warrants of the company originally issued on October 17, 2019. The warrants, of which 1,549,052 are available to be extended, are exercisable for common shares of the company at a price of $1.75/common share and are set to expire on October 17, 2022,  will now expire on July 17, 2023, an extension of 9 months. All other terms of the warrants, including the exercise price, remain unchanged. There are 1,661,552 warrants remaining available for exercise including 112,500 warrants held directly or indirectly by insiders of the company which will not be extended.
Seeking Alpha • Sep 13

Medicenna, Merck enter clinical trial collaboration to evaluate combo cancer treatment

Medicenna Therapeutics (NASDAQ:MDNA) on Tuesday said it had entered into a clinical trial collaboration and supply agreement with Merck (NYSE:MRK) to evaluate its agonist in combination with cancer drug Keytruda in its ongoing phase 1/2 study named ABILITY. Medicenna's (MDNA) agonist, MDNA11, is being assessed in the early- to mid-stage trial as a monotherapy and in combination with MRK's Keytruda to treat patients with cancerous tumors. As per the clinical trial collaboration deal, MDNA will sponsor the study and MRK will supply Keytruda. "Although we believe that MDNA11 has great potential as a single agent, combining it with Keytruda may significantly enhance therapeutic benefit in different types of cancer, potentially maximizing the value of MDNA11," MDNA CEO Fahar Merchant said in a statement. MDNA stock +1.5% to $1.03 in afternoon trading.
Seeking Alpha • Aug 15

Medicenna Therapeutics GAAP EPS of -$0.07 in-line

Medicenna Therapeutics press release (NASDAQ:MDNA): Q1 GAAP EPS of -$0.07 in-line. Medicenna had cash, cash equivalents, and marketable securities of $19.3 million at June 30, 2022, compared to $20.5 million at March 31, 2022.
Seeking Alpha • Aug 08

Medicenna Therapeutics stock slides on launch of units offering

Medicenna Therapeutics (NASDAQ:MDNA) shares fell 6% in Monday's extended session after the immunotherapy company announced the launch of an underwritten public offering of units in the U.S. Each unit will be comprised of one common share and one warrant to purchase common shares. The offering is expected to be priced in the context of the market, with the final terms to be determined at the time of pricing. The company plans to use the net proceeds primarily to fund the clinical development of MDNA11, the pre-clinical development of a BiSKIT candidate, working capital and for general corporate purposes.

Earnings and Revenue Growth Forecasts

OTCPK:MDNA.F - Analysts future estimates and past financials data (CAD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/202937-26-86193
3/31/20287-44-99-223
3/31/20271-34-57873
3/31/2026N/A-20-28-192
12/31/2025N/A-13-18-18N/A
9/30/2025N/A-14-17-17N/A
6/30/2025N/A-13-18-18N/A
3/31/2025N/A-12-17-16N/A
12/31/2024N/A-27-16-16N/A
9/30/2024N/A-27-17-17N/A
6/30/2024N/A-26-15-15N/A
3/31/2024N/A-25-16-16N/A
12/31/2023N/A-15-14-14N/A
9/30/2023N/A-12-13-13N/A
6/30/2023N/A-9-14-14N/A
3/31/2023N/A-10-13-13N/A
12/31/2022N/A-9-13-13N/A
9/30/2022N/A-13-16-16N/A
6/30/2022N/A-20-21-21N/A
3/31/2022N/A-23-24-24N/A
12/31/2021N/A-25-23-23N/A
9/30/2021N/A-26-20-20N/A
6/30/2021N/A-21-17-17N/A
3/31/2021N/A-17-15-15N/A
12/31/2020N/A-14-16-16N/A
9/30/2020N/A-11-14-14N/A
6/30/2020N/A-9-5-5N/A
3/31/2020N/A-8-5-5N/A
12/31/2019N/A-7-5-5N/A
9/30/2019N/A-6N/A-5N/A
6/30/2019N/A-5N/A-8N/A
3/31/2019N/A-5N/A-8N/A
12/31/2018N/A-5N/A-9N/A
9/30/2018N/A-5N/A-10N/A
6/30/2018N/A-6N/A-11N/A
3/31/2018N/A-7N/A-10N/A
12/31/2017N/A-11N/A-10N/A
9/30/2017N/A-11N/A-8N/A
6/30/2017N/A-10N/A-8N/A
3/31/2017N/A-8N/A-7N/A
12/31/2016N/A-3N/A-6N/A
9/30/2016N/A-2N/A-5N/A
6/30/2016N/A-1N/A-4N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MDNA.F is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MDNA.F is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MDNA.F is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MDNA.F's revenue (62.8% per year) is forecast to grow faster than the US market (12.1% per year).

High Growth Revenue: MDNA.F's revenue (62.8% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: MDNA.F's Return on Equity is forecast to be low in 3 years time (14%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/03 14:05
End of Day Share Price 2026/06/03 00:00
Earnings2025/12/31
Annual Earnings2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Medicenna Therapeutics Corp. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Charles ZhuGuggenheim Securities, LLC
Swayampakula RamakanthH.C. Wainwright & Co.
Dev PrasadLucid Capital Markets